Did you know that Toujeo U-300 insulin pens are good for 56 days once opened? And that the max dose for Tresiba U-200 FlexTouch Pen is 160 units?
For our latest version of our printed PocketCards, we now include the number of pens in a box, max injection dose, total insulin amount per pen, and shelf life on the Concentrated Insulin Card. We also added Lyumjev KwikPen u200 insulin.
When determining the best insulin for people taking concentrated insulins, shelf life, max dosing, and total units of insulin in each device are important considerations.
We have also updated the GFR parameters for SGLT2 Inhibitors. This class of medication not only substantially lowers blood glucose but also has a profound impact on renal protection.
As more trial data become available, the GFR cutoff levels may change, so periodically refer to the package insert (PI) or our DES electronic pocket care version, for the most up-to-date information.
We update the printed version of our PocketCard once or twice a year.
We update our electronic PocketCard on an ongoing basis.
Fortunately, we can immediately update our electronic version of the PocketCard on our website and CDCES Coach App to reflect the latest medication recommendations and guidelines. In the electronic version, we also include that the GLP-1 Exenatide (Bydureon) is now approved for peds, age 10 and older and the GFR cut-off for empagliflozin is now approved for a GFR 30 or greater (please see package insert for details).
Becoming Board Certified in Advanced Diabetes Management (BC-ADM) provides an opportunity for diabetes specialists with an advanced degree in their field (plus a professional license as an advanced practice nurse, registered dietitian, registered pharmacist, or provider) to increase the breadth and depth of their diabetes knowledge. The scope of advanced diabetes practice includes management skills such as medication adjustment, medical nutrition therapy, exercise planning, counseling for behavior management, and psychosocial issues.
Attaining optimal diabetes management includes using a person-centered approach coupled with assessment, screening, management, and monitoring of acute and chronic diabetes co conditions. This webinar will review changes in requirements for this year’s exam eligibility and test format, strategies to succeed along with a review of study tips and test-taking tactics. We will review sample test questions and the reasoning behind choosing the right answers. We hope you can join us for this webinar.
Can’t make it live? All paid registrants are guaranteed access to the video presentation, handouts and podcasts.
Sign up for Diabetes Blog Bytes – we post one daily Blog Byte from Monday to Friday. And of course, Tuesday is our Question of the Week. It’s Informative and FREE! Sign up below!
Accreditation: Diabetes Education Services is an approved provider by the California Board of Registered Nursing, Provider 12640, and Commission on Dietetic Registration (CDR), Provider DI002. Since these programs are approved by the CDR it satisfies the CE requirements for the CDCES regardless of your profession.
The use of DES products does not guarantee the successful passage of the CDCES exam. CBDCE does not endorse any preparatory or review materials for the CDCES exam, except for those published by CBDCE.
The Food and Drug Administration (FDA) just approved another GLP-1 RA for use in children ages 10-17 with diabetes.
The injectable extended-release exenatide (Bydureon) is now the second glucagonlike peptide-1 receptor agonist (GLP-1 RA) approved for use in pediatric type 2 diabetes and the first with once-weekly administration. Liraglutide (Victoza) a daily injectable GLP-1 RA received approval for pediatric use in 2019 and metformin an oral biguanide has long been FDA approved for use children ten and older with type 2 diabetes.
During the annual scientific sessions of the American Diabetes Association, speakers expressed alarm about the rise in youth developing type 2 diabetes, noting that the condition typically progresses more rapidly and is less likely to respond well to metformin, compared with adults.
The approval was based on a 24-week, double-blind, placebo-controlled study in 82 children with type 2 diabetes aged 10 and older. They were randomized to 2 mg once-weekly exenatide extended release or placebo. At week 24, hemoglobin A1c in those randomized to the drug had dropped by 0.25 percentage points, compared with a 0.45 percentage point increase in the placebo group.
Based on the ADA Standards of Care for treating pediatrics with diabetes, the first treatment includes weight loss and exercise plus first line medications metformin and insulin if A1c is 8.5% or greater.
Furthermore, the initiation of any GLP-1 RA is only recommended once pancreatic antibodies are determined to be absent and if A1c goals have not met despite the initiation of metformin or insulin (see ADA standards algorithm below stating consider adding liraglutide (GLP-1 RA))
We have updated the electronic version of our Injectable PocketCard to reflect this update.
Download our Medication PocketCards today on our Website PocketCards , or CDCES Coach App (free).
Want to learn more about this topic and more?
Did you miss the live conference? No worries! You can register now to watch on-demand
Whether you are new to diabetes or a seasoned expert, you’ll benefit from this virtual conference with the latest research plus critical content that you can immediately apply to your clinical practice.
If you are seeking a state-of-the-art review of current diabetes care, this course is for you. Our team has been fine-tuning this course for over fifteen years, and we know what you need. This program can also be a great addition to your CDCES or BC-ADM exam study plan.
Team of expert faculty includes:
In addition to informative lectures, we also use group activities and case studies to highlight the essential knowledge, skills, and strategies needed to succeed in diabetes education today!
CEs: Includes over 30 CEs
Program Info: 2021 Diabetes Educator Course Flyer & Schedule (subject to change)
Speakers: View Conference Faculty.
Dates: Your registration fee includes access to FREE podcast and all recorded webinars for one year.
Two Registration Options
Virtual DiabetesEd Specialist Conference Deluxe | Oct. 6-8 | 30+ CEs
Deluxe Virtual Program for $459 includes:
+Plus Syllabus, Standards and Swag:
2021 Diabetes Educator Course Flyer & Schedule (subject to change)
Virtual DiabetesEd Specialist Conference Basic | Oct. 6-8 | 30+ CEs
Basic virtual program for $359 includes:
2021 Diabetes Educator Course Flyer & Schedule (subject to change)
Team of Experts: Our team of expert faculty has been fine-tuning this course for over fifteen years and we know what you need to succeed! In addition to informative lectures, we also use group activities and case studies to highlight the essential knowledge, skills, and strategies needed to succeed in diabetes education today!
When you register for our Virtual Course, you have immediate access to these Bonus DiabetesEd University Online Courses – for FREE!
2021 Diabetes Educator Course Flyer & Schedule (subject to change)
Sign up for Diabetes Blog Bytes – we post one daily Blog Byte from Monday to Friday. And of course, Tuesday is our Question of the Week. It’s Informative and FREE! Sign up below!
Accreditation: Diabetes Education Services is an approved provider by the California Board of Registered Nursing, Provider 12640, and Commission on Dietetic Registration (CDR), Provider DI002. Since these programs are approved by the CDR it satisfies the CE requirements for the CDCES regardless of your profession.*
The use of DES products does not guarantee the successful passage of the CDCES exam. CBDCE does not endorse any preparatory or review materials for the CDCES exam, except for those published by CBDCE.
Since heart disease is the leading cause of death in people with diabetes, these new treatment options including PCSK9 Inhibitors and ACL Inhibitors, offer hope of decreasing cardiovascular mortality and morbidity. In addition rates of Chronic Kidney Disease (CKD) rates are rising worldwide and people with diabetes account for the majority of people receiving treatment for end-stage renal disease.
The new nonsteroidal Selective Mineralcorticoid Antagonists reduce the risk of kidney function decline and failure, plus reduce risk of cardiovascular death. We asked our PharmD experts to update our Cheat Sheets with the latest info and provide a summary of these medication classes, action and considerations. Special thanks to our contributing experts Diana Isaacs, PharmD, BCPS, BCACP, BC-ADM, CDCES, FADCES, FCCP and Kristapor Thomassian, PharmD, BCPS.
Download Updated Cheat Sheets Here
PCSK9 Inhibitors (proprotein convertase subtillisin / kexin type 9)
This class of drugs are monoclonal antibodies designed to bind to the PCSK9 enzyme in the liver. PCSK9 enzyme is involved in inactivating LDL receptors, resulting in continued high levels of LDL circulating in the blood. The PCSK9 inhibitors (monoclonal antibodies) bind to the enzyme and increase the LDL receptors, helping reduce circulating LDL in the blood by appropriately metabolizing LDL in the liver.
There are specific FDA approved indications for this class of medications. Please refer to appropriate guidelines to determine if the individual meets criteria for agents in this class for treatment.
ACL Inhbitor (Adenosine Triphosphte-citrate Lyase)
This class of drug is designed to bind to the ATP-citrate Lyase enzyme. The ATP-citrate Lyase enzyme is the one of the initial enzymes involved in Cholesterol synthesis. Statins are the main class of agents we currently use to help block the HMG-CoA reductase enzyme, one of the primary enzymes involved in cholesterol production. The ACL inhibitor works upstream on the same cascade to help reduce cholesterol production, to achieve additional LDL lowering.
Nonsteroidal Selective Mineralocorticoid Receptor Antagonist
This class of drug is designed to bind to the Mineralocorticoid receptor. Mineralocorticoid receptors are found in regions most important for regulating electrolytes like sodium and potassium in key organs such as the kidney, heart and brain. Reducing the progression of chronic kidney disease (CKD) is one of our most important goals in keeping preventing end stage renal disease and CB events. Excess aldosterone production, the primary steroid based mineralocorticoid found in our bodies, has been implicated in nephrololgy and cardiovascular pathophysiology. The mineralocorticoid receptor antagonist blocks the effects of aldosterone and reduces the risk of kidney function decline as well as heart failure.
Want to learn more about this topic and more?
Did you miss the live conference? No worries! You can register now to watch on-demand
Whether you are new to diabetes or a seasoned expert, you’ll benefit from this virtual conference with the latest research plus critical content that you can immediately apply to your clinical practice.
If you are seeking a state-of-the-art review of current diabetes care, this course is for you. Our team has been fine-tuning this course for over fifteen years, and we know what you need. This program can also be a great addition to your CDCES or BC-ADM exam study plan.
Team of expert faculty includes:
In addition to informative lectures, we also use group activities and case studies to highlight the essential knowledge, skills, and strategies needed to succeed in diabetes education today!
CEs: Includes over 30 CEs
Program Info: 2021 Diabetes Educator Course Flyer & Schedule (subject to change)
Speakers: View Conference Faculty.
Dates: Your registration fee includes access to FREE podcast and all recorded webinars for one year.
Two Registration Options
Virtual DiabetesEd Specialist Conference Deluxe | Oct. 6-8 | 30+ CEs
Deluxe Virtual Program for $459 includes:
+Plus Syllabus, Standards and Swag:
2021 Diabetes Educator Course Flyer & Schedule (subject to change)
Virtual DiabetesEd Specialist Conference Basic | Oct. 6-8 | 30+ CEs
Basic virtual program for $359 includes:
2021 Diabetes Educator Course Flyer & Schedule (subject to change)
Team of Experts: Our team of expert faculty has been fine-tuning this course for over fifteen years and we know what you need to succeed! In addition to informative lectures, we also use group activities and case studies to highlight the essential knowledge, skills, and strategies needed to succeed in diabetes education today!
When you register for our Virtual Course, you have immediate access to these Bonus DiabetesEd University Online Courses – for FREE!
2021 Diabetes Educator Course Flyer & Schedule (subject to change)
Sign up for Diabetes Blog Bytes – we post one daily Blog Byte from Monday to Friday. And of course, Tuesday is our Question of the Week. It’s Informative and FREE! Sign up below!
Accreditation: Diabetes Education Services is an approved provider by the California Board of Registered Nursing, Provider 12640, and Commission on Dietetic Registration (CDR), Provider DI002. Since these programs are approved by the CDR it satisfies the CE requirements for the CDCES regardless of your profession.*
The use of DES products does not guarantee the successful passage of the CDCES exam. CBDCE does not endorse any preparatory or review materials for the CDCES exam, except for those published by CBDCE.
Semglee (insulin glargine-yfgn) is a biosimilar basal insulin with the same chemical composition as insulin glargine. However, since it is a biosimilar, it is a less costly version of this widely popular basal insulin. Up until now, pharmacists could not make “pharmacy-level substitution”—much like how generic drugs are substituted for brand name drugs, without provider approval.
With this new FDA approval, an interchangeable biosimilar product may be substituted for the reference product without the intervention of the prescriber. Biosimilars marketed in the U.S. typically have launched with initial list prices 15% to 35% lower than comparative list prices of the reference products.
Bottom line, the pharmacist can now interchange or substituted semglee for its reference product Lantus (insulin glargine) without prescriber approval.
“This is a momentous day for people who rely daily on insulin for treatment of diabetes, as biosimilar and interchangeable biosimilar products have the potential to greatly reduce health care costs,” said Acting FDA Commissioner Janet Woodcock, M.D.
This also has implications for future, lower cost biosimilars says Dr. Woodcock. “Today’s approval of the first interchangeable biosimilar product furthers FDA’s longstanding commitment to support a competitive marketplace for biological products and ultimately empowers patients by helping to increase access to safe, effective and high-quality medications at potentially lower cost.”
Semglee (insulin glargine-yfgn), offered in 10 mL vials and 3 mL prefilled pens, is administered subcutaneously once daily.
Access to affordable insulin is critical and the approval of this first biosimilar heralds good news for future biosimilar interchangeability.
Want to learn more about this topic and more?
Did you miss the live conference? No worries! You can register now to watch on-demand
Whether you are new to diabetes or a seasoned expert, you’ll benefit from this virtual conference with the latest research plus critical content that you can immediately apply to your clinical practice.
If you are seeking a state-of-the-art review of current diabetes care, this course is for you. Our team has been fine-tuning this course for over fifteen years, and we know what you need. This program can also be a great addition to your CDCES or BC-ADM exam study plan.
Team of expert faculty includes:
In addition to informative lectures, we also use group activities and case studies to highlight the essential knowledge, skills, and strategies needed to succeed in diabetes education today!
CEs: Includes over 30 CEs
Program Info: 2021 Diabetes Educator Course Flyer & Schedule (subject to change)
Speakers: View Conference Faculty.
Dates: Your registration fee includes access to FREE podcast and all recorded webinars for one year.
Two Registration Options
Virtual DiabetesEd Specialist Conference Deluxe | Oct. 6-8 | 30+ CEs
Deluxe Virtual Program for $459 includes:
+Plus Syllabus, Standards and Swag:
2021 Diabetes Educator Course Flyer & Schedule (subject to change)
Virtual DiabetesEd Specialist Conference Basic | Oct. 6-8 | 30+ CEs
Basic virtual program for $359 includes:
2021 Diabetes Educator Course Flyer & Schedule (subject to change)
Team of Experts: Our team of expert faculty has been fine-tuning this course for over fifteen years and we know what you need to succeed! In addition to informative lectures, we also use group activities and case studies to highlight the essential knowledge, skills, and strategies needed to succeed in diabetes education today!
When you register for our Virtual Course, you have immediate access to these Bonus DiabetesEd University Online Courses – for FREE!
2021 Diabetes Educator Course Flyer & Schedule (subject to change)
Sign up for Diabetes Blog Bytes – we post one daily Blog Byte from Monday to Friday. And of course, Tuesday is our Question of the Week. It’s Informative and FREE! Sign up below!
Accreditation: Diabetes Education Services is an approved provider by the California Board of Registered Nursing, Provider 12640, and Commission on Dietetic Registration (CDR), Provider DI002. Since these programs are approved by the CDR it satisfies the CE requirements for the CDCES regardless of your profession.*
The use of DES products does not guarantee the successful passage of the CDCES exam. CBDCE does not endorse any preparatory or review materials for the CDCES exam, except for those published by CBDCE.
A new aqueous glucagon analog formulation has been FDA approved and should be available in pharmacies later this year.
Dasiglucagon (Zegalogue) is an effective, reliable treatment to increase glucose levels following insulin-induced hypoglycemia in children and adolescents with type 1 diabetes. This conclusion is based on a double-blind study recently published in Diabetes Care, April 2021.
This ready-to-use, next-generation formulation is approved for ages 6 or older. Subcutaneous injection sites include the abdomen, buttocks, thighs, and upper arms. This prefilled syringe contains a stable liquid glucagon analog and can be stored for one year at room temperature.
The investigators report that dasiglucsagon treatment was well tolerated, with the usual adverse effects (nausea and vomiting) expected from glucagon treatment.
The dose of dasiglucagon is 0.6 mg to treat severe hypoglycemia in pediatrics over the age of 6 years and adults with diabetes. Download our Glucagon PocketCard to post and share with colleagues and people living with diabetes.
As with all glucagon injections, dasiglucagon can cause nausea and vomiting. After the dose is administered, roll the person on the side and seek medical help. When awake, give oral carbohydrates ASAP when safe to swallow, and consult package insert for detailed guidelines!
Preventing Future Episodes of Hypoglycemia
Most importantly, encourage people experiencing a severe low blood sugar to determine the cause of the hypoglycemic event and implement strategies to prevent future lows. Our free Glucagon Card is the perfect teaching tool to help reinforce prevention and early action!
Thank you for helping get the word out about these rescue medications for severe hypoglycemia. This hormone injection saves lives and is a must-have for anyone living with type 1 diabetes or those with type 2 on intensive insulin therapy.
Want to learn more about this topic? Join us for our
Why do the blood sugars keep dropping after meals? Is the basal insulin set correctly? What adjustments are needed for exercise?
During this 60 -90 minute webinar Coach, Beverly addresses each of these glucose mysteries and more, using a person-centered approach. She describes a stepwise approach to evaluate glucose patterns and correct common issues encountered by people living with type 1 diabetes.
By attending this webinar, you will gain confidence in evaluating glucose patterns and making recommendations for improvement.
Objectives
Including Brand New Specialty Courses!
Can’t join live? No worries, we will record the webinar and post it to the Online University!
Sign up for Diabetes Blog Bytes – we post one daily Blog Byte from Monday to Friday. And of course, Tuesday is our Question of the Week. It’s Informative and FREE! Sign up below!
Accreditation: Diabetes Education Services is an approved provider by the California Board of Registered Nursing, Provider 12640, and Commission on Dietetic Registration (CDR), Provider DI002. Since these programs are approved by the CDR it satisfies the CE requirements for the CDCES regardless of your profession.*
The use of DES products does not guarantee the successful passage of the CDCES exam. CBDCE does not endorse any preparatory or review materials for the CDCES exam, except for those published by CBDCE.
JR is 64 years old, in hospital with type 2 diabetes and COVID. JR normally manages their diabetes with metformin, but during this inpatient stay, JR is on prednisone therapy which has spiked sugar levels into the 250 mg/dl to 350 range. JR is receiving bolus insulin sliding scale with meals and bedtime glargine, but blood sugars are persistently elevated. To improve outcomes for JR, it is important to keep blood glucose levels less than 180 mg/dl, but what should we recommend to get glucose to goal?
What are some strategies to get blood sugar to target while on steroids?
There is no consensus on the best approach to manage this situation. Up until this point in history, steroid-induced hyperglycemia was mostly found in people with diabetes in COPD, those undergoing chemotherapy or in post-transplant situations.
With the COVID pandemic, many people with diabetes in hospitals and at home, are on steroids. Health care professionals are trying to figure out how to lower glucose levels.
For people with type 2 diabetes and COVID, the latest research indicates that sitagliptin (Januvia) not only helps maintain blood glucose but also decreases the inflammatory response associated with COVID infections. If not contraindicated, sitagliptin can be used in conjunction with insulin, to treat the extreme insulin resistance and hyperglycemia caused by steroid therapy.
To treat steroid induced hyperglycemia, we are going to call on our old insulin friend, NPH. Neutral Protamine Hagedorn (NPH) is an intermediate acting basal insulin. NPH insulin is made by mixing regular insulin and protamine in exact proportions with zinc and phenol such that a neutral-pH is maintained and crystals form.
NPH insulin is cloudy and has an onset of 1–4 hours. Its peak is 6–10 hours and its duration is about 10–16 hours.
Steroids have their highest potency at 4-12 hours, with the exception of the very potent dexamethasone, which has a half life of 1-2 days.
However, with all steroids, including dexamethasone, people will experience elevated glucose values after breakfast, lunch, dinner, and at bedtime but will have a significant drop toward normal glucose overnight.
Therefore, hyperglycemia is greatest 1–2 hours after a meal, with persistent elevation until the following meal, followed by a return to normal overnight.
NPH Insulin Dosing Strategies
There are several articles (see below) that recommend a variety of NPH dosing strategies. Generally, insulin dosing is based on a combination of steroid dose and body weight. For those on lower dose steroid (ie less than 40 mg prednisone daily) a starting NPH insulin dose of 0.1 – 0.2 units per kg is reasonable. If JR weighs 100 kg, that means 10 to 20 units of NPH daily.
If JR is on a higher steroid dose, or blood sugars are extremely elevated, JR may need 0.3 units/kg or 30 units of NPH daily. Of course, we also need to keep nutritional status in mind as we determine best dose. People who are not eating or NPO, will require less insulin, even in the presence of steroids.
The timing of NPH administration matches the timing of the steroid therapy.
In addition, coverage for carbohydrates at meals and correction insulin bolus for hyperglycemia can help prevent post-prandial hyperglycemia.
A simple getting started strategy – 70/30 Insulin
A simple strategy I have used over many years, that I find safe and effective, is giving the basal-bolus premixed 70/30 insulin with the morning dose of steroid. A safe starting range is around 10 units in the morning and gradually increases 10-20% daily to get glucose to target. In addition, bolus coverage for carbs and hyperglycemia can be given at lunch and dinner.
Since blood sugars trend down overnight, nighttime NPH insulin is not usually needed.
Keeping it flexible
As the person starts recovering and steroid doses are gradually tapered down, it is important to also decrease the NPH insulin dose and bolus insulins to prevent hypoglycemia.
In conclusion:
Keeping blood sugars on target improves outcomes. For people with diabetes, steroids can cause a hyperglycemic crisis. Thoughtful and progressive management using NPH and bolus insulins can turn the tide and help get blood glucose levels to goal.
Join Coach Beverly at our Virtual Conference for more information on COVID and Diabetes Management Strategies.
Glycemic Control in Hospitalized Patients with Diabetes Receiving Corticosteroids Using a Neutral Protamine Hagedorn Insulin Protocol: A Randomized Clinical Trial. Khowaja A, Alkhaddo JB, Rana Z, Fish L. Diabetes Ther. 2018 Aug;9(4):1647-1655.
How to Manage Steroid Diabetes in the Patient With Cancer
David S. Oyer, MD, FACE, Ajul Shah, BS, and Susan Bettenhausen, APRN, CDE, 2006
Whether you are new to diabetes or a seasoned expert, you’ll benefit from this virtual conference with the latest research plus critical content that you can immediately apply to your clinical practice.
Prepare for CDCES or BC-ADM certification or earn hours for renewal.
If you are interested in taking the CDCES or BC-ADM exam or are seeking a state of the art review of current diabetes care, this course is for you. Our team has been fine-tuning this course for over fifteen years, and we know what you need.
Team of expert faculty includes:
In addition to informative lectures, we also use group activities and case studies to highlight the essential knowledge, skills, and strategies needed to succeed in diabetes education today!
Your registrations include access to all the Online Sessions plus Bonus Courses through December 31st, 2021.
Virtual DiabetesEd Specialist Conference | April 15-17, 2021
Whether you are new to diabetes or a seasoned expert, you’ll benefit from this virtual conference with the latest research plus critical content that you can immediately apply to your clinical practice.
Entire Program Fee: $399
Dates: April 15-17, 2021
Live Webinar Schedule: All webinars start and end times are in Pacific Standard Time
Coach Beverly Thomassian, RN, MPH, BC-ADM, CDCES
Author, Nurse, Educator, Clinician and Innovator, Beverly has specialized in diabetes management for over twenty years. As president and founder of Diabetes Educational Services, Beverly is dedicated to optimizing diabetes care and improving the lives of those with diabetes.
Diana Isaacs, PharmD, BCPS, BC-ADM, BCACP, CDCES
We are thrilled to welcome our newest speaker, Diana Isaacs, who will be joining our Virtual and Live Courses!
Dr. Isaacs was named 2020 AADE Diabetes Educator of the Year for her educational platform promoting the use of CGM for people with diabetes and other innovations. Dr. Isaacs was awarded the Ohio Pharmacists Association Under 40 Award in 2019. Dr. Isaacs has served in leadership roles for several pharmacies and diabetes organizations. She has numerous diabetes publications and research projects with a focus on medications, CGM and diabetes technology.
As the CGM Program Coordinator and clinical pharmacist specialist in the Cleveland Clinic Diabetes Center, Dr. Isaacs brings a wealth of clinical knowledge combined with extensive research experience to this program.
Diabetes Meds and Insulin Toolkit – with Dr. Diana Isaacs | 4.0 CEs
April 15 10:30 am – 12:30 BREAK and 1:15 – 3:15 PST
*Topics include:
Technology Toolkit with CV Management Update – Dr. Diana Isaacs | 4.0 CEs –
April 16 with 8:30—12:30 am
Ashley LaBrier, MS, RD, CDCES
Ashley is an educator, dietitian, and the Diabetes Education Program Coordinator at the Salinas Valley Medical Clinic’s Diabetes & Endocrine Center. Her work with people living with diabetes focuses on the value of healthy nutrition and movement to improve well-being.
Ashley is passionate about providing person-centered education to empower those who live with diabetes. Having been diagnosed with type 1 diabetes herself nearly 20 years ago, she combines her professional knowledge with personal experience and understanding.
April 17 with Ashley LaBrier, MS, RD, CDCES
8:30 am — 12:30 pm PST
*Dates and times subject to change. Course start and end time are for Pacific Standard Timezone.
Bonus Courses – Course registration includes FREE enrollment into our Level 2 Standard of Care Course Series including:
Team of expert faculty includes:
In addition to informative lectures, we also use group activities and case studies to highlight the essential knowledge, skills, and strategies needed to succeed in diabetes education today!
Prepare for CDCES or BC-ADM certification or earn hours for renewal.
Your registrations include access to all the Online Sessions plus Bonus Courses through December 31st, 2021.
This virtual program includes:
3 day live webinar courses from April 15th-17th (20 CEs) + enrollment in our Bonus Bundle (14.0+ CEs) from now through December 2021.
View full Conference Schedule and Faculty.
Sign up for Diabetes Blog Bytes – we post one daily Blog Byte from Monday to Friday. And of course, Tuesday is our Question of the Week. It’s Informative and FREE! Sign up below!
Accreditation: Diabetes Education Services is an approved provider by the California Board of Registered Nursing, Provider 12640, and Commission on Dietetic Registration (CDR), Provider DI002. Since these programs are approved by the CDR it satisfies the CE requirements for the CDCES regardless of your profession.*
The use of DES products does not guarantee the successful passage of the CDCES exam. CBDCE does not endorse any preparatory or review materials for the CDCES exam, except for those published by CBDCE.
What are the treatment options for people with type 1 diabetes with a COVID infection hospitalized for Diabetes KetoAcidosis (DKA)?
The typical treatment for DKA is fluids coupled with an IV insulin drip. Given the frequent monitoring and ICU bed required for treatment of DKA with an insulin drip, there has been a renewed interest in treating DKA with subcutaneous or sub-q insulin.
But after doing some research, I discovered an excellent 2004 paper co-authored by Dr. Guillermo Umpierrez et al. on using Sub-Q Insulin to Treat DKA. After completing a study comparing treatment of DKA using sub-q insulin vs. insulin drip, the author’s conclude that sub-Q insulin treatment is a safe and effective alternative treatment to IV insulin in the management of people with mild or moderate DKA.
With a little more digging, I found 2 more recent papers that suggest considering Sub-Q insulin treatment as an option for mild or moderate DKA.
It is important to note that sub-Q insulin treatment for DKA is NOT recommended for patients with arterial hypotension, severe and complicated DKA, or with HHS.
Insulins: Use either rapid acting lispro or aspart insulin.
1st Bolus: Starting dose is 0.1 or 0.2 or 0.3 units/kg of insulin (depending on initial blood glucose and clinical presentation)
Example: Pt weighs 100 kg, give 100kg x 0.1 – 0.2 – 0.3 units/kg of insulin = 10 or 20 or 30 units insulin sub-q bolus respectively.
Next Step – Sub-q insulin every 2 hours | Give 0.1 – 0.2 units of insulin /kg every 2 hours until blood glucose is less than 250.
Example: Pt weighs 100 kg, give 100kg x 0.1 – 0.2 units/kg of insulin = 10 or 20 units insulin sub-q bolus respectively every 2 hours.
Blood glucose less than 250 | Now give 1/2 the sub-q insulin dose every 2 hours. Calculate 0.05 to 0.1 units/kg every 2 hours until glucose at target and ketosis is resolved.
Example: Pt weighs 100 kg, give 100kg x 0.05 – 0.1 units/kg of insulin = 5 or 10 units insulin sub-q bolus respectively every 2 hours.
Using scheduled subcutaneous insulin allows for safe and effective treatment in the emergency room and step-down units without the need for ICU care. Umpierrez et al
Please see reference chart and articles below for more detailed information.
Of course, fluid and electrolyte status needs to be assessed before starting insulin.
If the K+ is less than 3.3, hold insulin and start with IV fluids (NS or LR) first with potassium replacement. Once the K is stable, start the insulin injection every 2 hours (see article and flow chart below).
Thank you for reading this article. Please share any feedback or your experiences using sub-q insulin for DKA. We always love to hear from you. You can email us at info@diabetesed.net
Eledrisi MS, Elzouki AN. Management of Diabetic Ketoacidosis in Adults: A Narrative Review. Saudi J Med Med Sci. 2020;8(3):165-173. doi:10.4103/sjmms.sjmms_478_19
Fayfman M, Pasquel FJ, Umpierrez GE. Management of Hyperglycemic Crises: Diabetic Ketoacidosis and Hyperglycemic Hyperosmolar State. Med Clin North Am. 2017;101(3):587-606. doi:10.1016/j.mcna.2016.12.011
Join Coach Beverly to learn more about causes and treatment of hyperglycemic crisis. (opens in a new tab)”>Find out more here>>
This course is included in: Level 2 – Standards of Care. Purchase this course individually for $19 or the entire bundle and save 70%.
This 60-minute course discusses common causes of hyperglycemia crises. Topics include hyperglycemia secondary to medications and insulin deprivation. The difference and similarities between Diabetes Ketoacidosis and Hyperosmolar Hyperglycemic Syndrome are also covered. Treatment strategies for all situations are included.
Topics include:
Sign up for Diabetes Blog Bytes – we post one daily Blog Byte from Monday to Friday. And of course, Tuesday is our Question of the Week. It’s Informative and FREE! Sign up below!
Accreditation: Diabetes Education Services is an approved provider by the California Board of Registered Nursing, Provider 12640, and Commission on Dietetic Registration (CDR), Provider DI002. Since these programs are approved by the CDR it satisfies the CE requirements for the CDCES regardless of your profession.*
The use of DES products does not guarantee the successful passage of the CDCES exam. CBDCE does not endorse any preparatory or review materials for the CDCES exam, except for those published by CBDCE.